Adlai Nortye Ltd

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, recently announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery). This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E receptor 4 (“EP4”) antagonist, with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: ‘TNT') (“CRT”) for the treatment of rectal cancer. The study has been developed and is being led by the Cancer Research (“CRUK”) Clinical Trials Unit (“CTU”) at the University of Leeds, with clinical leadership teams from consultant oncologists Prof Simon Gollins and Prof Mark Saunders.

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year?

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Elevance Health (ELV) have performed compared to their sector so far this year.

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the Completion of Patient Enrollment in Global Phase III Clinical Trial (BURAN) of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC in more than 180 sites around the world, spanning over 18 markets in North America, Europe, Asia, and South America.

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on innovative oncology drugs, and Nucleai, a pathology-based AI-powered biomarker discovery and diagnostics company, is pleased to announce today the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”. The study assessed a novel methodology for identifying recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) patients that are likely to benefit from combination Buparlisib + paclitaxel treatment. The focus is to examine AI-based structuring and analyze H&E images to identify spatial features associated with clinical outcomes.

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Newly listed Adlai Nortye has yet to bring any products to market and has lost more than $130 million in just over two years. ANL's key drug candidate is a PI3K inhibitor now in global trials, even as several candidates from the same class have suffered setbacks in recent years. Buparlisib's approval in one or more major markets would considerably brighten the company's prospects.

Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the closing of its previously announced initial public offering of 2,500,000 American depositary shares (“ADSs”), each representing three Class A ordinary shares at a public offering price of US$23.00 per ADS. All of the ADSs were offered by Adlai Nortye. In addition, Nippon Kayaku Co., Ltd., a chemical company headquartered in Japan, acquired a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private placement concurrent with the closing of the public offering at the same per share purchase price. Adlai Nortye received aggregate gross proceeds of US$57.5 million from the public offering (before deducting underwriting discounts and commissions and offering expenses) and US$40.0 million from the concurrent private placement.

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Birkenstock Holding Plc

Gamer Pakistan Inc

Lead Real Estate Co Ltd

VS MEDIA Holdings Ltd

The third quarter wrapped up with four IPOs and eight pipeline additions. Eight issuers submitted initial filings this past week. The October IPO market looks like it will be off to a quiet start, with no IPOs currently scheduled for the week ahead. ANL, VSME, LRE, GPAK, MTDC, KHIW, BTOC, BIRK

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the pricing of its initial public offering of 2,500,000 American depositary shares (“ADSs”), or 2,875,000 ADSs if the underwriters exercise their over-allotment option in full, each representing three Class A ordinary shares, at a public offering price of US$23.00 per ADS. All of the ADSs were offered by Adlai Nortye. In addition, an investor will acquire a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private placement concurrent with the closing of the public offering at the same per share purchase price. Adlai Nortye expects to receive aggregate gross proceeds of US$97.5 million, including US$57.5 million from the public offering (before deducting underwriting discounts and commissions and offering expenses, and not taking into account potential exercise of the underwriters' over-allotment option) and US$40.0 million from the concurrent private placement. Assuming the over-allotment option is exercised in full, the aggregate gross proceeds to be received by Adlai Nortye may reach up to approximately US$106.1 million.

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Airbnb

ARM Holdings PLC

Instacart (Maplebear Inc.)

Renaissance IPO ETF

Renaissance International IPO ETF

Inspire Veterinary Partners Inc

Snowflake

There was just one pricing this past week, which was excluded from our IPO stats, while holdover biotech Adlai Nortye did not get done. Filing activity reached a six-month high in August, and six issuers filed to raise $100 million or more, the most since January. Veterinary hospital operator Inspire Veterinary Partners priced at the low end to raise $6 million at a $41 million market cap.

U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap

Aurora Acquisition Corp

Black Spade Acquisition Co

Fitell Corp

LQR House Inc

Neuraxis Inc

Nature Wood Group Ltd

VinFast Auto Ltd

Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time through the August break, the SPAC market is churning out deals. Three IPOs are currently scheduled to list in the week ahead, although other small issuers may join the calendar during the week.

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials for solid tumors and head and neck squamous cell cancer. The global market for head and neck cancer treatments is expected to reach $3.5 billion by 2030.

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO

Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbol “ANL”.

Cancer treatment company Adlai Nortye sets terms in IPO

Adlai Nortye Ltd. has filed to raise $115 million in a U.S. IPO, although the final figure may differ. The firm is a clinical stage biopharma developing immunotherapy treatments for solid tumor cancer conditions. Adlai Nortye is in Phase 3 trials for its lead candidate and has several major pharma collaboration and licensing relationships, a strong positive in my view.

Adlai Nortye Ltd. Begins U.S. IPO Rollout

News for Adlai Nortye Ltd Stock (ANL)